You learned to question Ozempic. The next injectable wave is asking the same question, and the evidence is thinner.

More than one in 10 Americans now take a GLP-1 drug like Ozempic or Wegovy for weight loss or diabetes. That generation learned to ask whether a weekly injection actually does what it is marketed to do. The next category is already on the pharmacy counter: growth-hormone-releasing peptides, small proteins that nudge the brain's pituitary gland to release more of the body's own growth hormone, sold as "natural" anti-aging shots through compounding pharmacies, telehealth prescribers, and longevity clinics (Scientific American).

Growth hormone itself is a small protein made by the pituitary gland at the base of the brain. It is released in pulses throughout the day and night, peaks during puberty, and then falls by as much as half every seven to ten years after that. In adults it helps regulate blood sugar, bone density, and muscle growth. The peptides being sold today, including sermorelin, tesamorelin, CJC-1295, and ipamorelin, are not growth hormone. They are secretagogues, compounds designed to nudge the pituitary to release more of the body's own growth hormone on the theory that a "natural" elevation is safer and more physiological than injecting the hormone directly (Scientific American).

The history that fuels the marketing runs through a 1990s trial often cited as the founding study of the field. In that work, Daniel Rudman and colleagues gave older men injectable growth hormone and reported changes in lean mass and fat that the press summarized as reversing roughly a decade of aging. The result has been cited for three decades as proof of concept, but it was a small, short study in men, and the authors themselves flagged the need for longer and larger work to weigh benefits against risks of diabetes, fluid retention, and other adverse effects (NEJM record of the trial thread). The compounds now being sold to consumers are not the hormone Rudman injected, and the evidence base on them has not filled in the gap (PubMed 18057338, PubMed 16352683).

Sermorelin, tesamorelin, CJC-1295, and ipamorelin reach consumers through compounding pharmacies that mix peptides on a per-patient basis, telehealth platforms that prescribe after a short consult, and a growing network of longevity clinics that package the injections with hormone panels and IV drips. The public face of that distribution includes podcaster Andrew Huberman, health coach Christian Poulos, and wellness author Mark Hyman, each of whom has promoted growth-hormone-releasing peptides to large audiences. The relevant fact is not that any of them is wrong. It is that consumer demand is now being shaped faster than the clinical literature can keep up (Scientific American).

Anne Cappola, an endocrinologist at the University of Pennsylvania, frames the consumer logic bluntly: "Anytime you have something that changes with age, particularly if it decreases, people say well, that must be why you age ... If you take growth hormone, then you may not age." Brad Anawalt, an endocrinologist at the University of Washington School of Medicine, walks readers through the basic biology, including a pituitary signal, a pulsed release, and downstream effects on IGF-1, blood sugar, and bone (Scientific American). The worry is not that growth hormone is unimportant. It is that raising it pharmacologically in adults whose levels have fallen for ordinary reasons can produce effects, including insulin resistance, fluid retention, joint pain, and in some populations a theoretical concern about promoting existing tumors through IGF-1, that the marketed trials have not been long or large enough to rule out (PubMed 20101189, PubMed 41545261).

Compounded peptides are mixed under pharmacy-board rules, not FDA approval pathways, and the same molecule can sit on a longevity clinic's menu without the kind of randomized, controlled evidence that would normally be required to put a drug on the market. A reader who has learned to ask whether a weekly GLP-1 injection is right for them is now being asked the same question about a different molecule, sold through a different channel, on a thinner evidence base (Scientific American explainer on the broader peptide craze).

The portable question, then, is not whether this compound is snake oil or a breakthrough. It is whether the pitch rests on a mechanism, the kind a textbook biology diagram can draw, or on a study of the actual product, in the actual people being pitched to, at the actual dose, for long enough to know what it does. Mechanism is cheap. The second half of that test is what the GLP-1 generation had to demand before it trusted the first injectable wave, and it is the same demand this one will have to make.